Cyclacel Pharmaceuticals (CYCC) 10-Q2007 Q1 Quarterly report

Filed: 9 May 07, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abroad, al, albeit, analog, appr, approach, behavior, broad, buy, cal, carcinoma, charter, choose, cli, clini, commo, competitor, composition, confidence, Contentsbelieve, ContentsCapital, Contentsderivative, Contentsdiscover, Contentsevent, Contentsexperienced, ContentsIntellectual, ContentsItem, Contentsposition, Contentsthere, contest, court, curren, CYCC, decide, deterioration, DIG, earliest, Entremed, entrenchment, es, est, estate, Europe, examination, expend, explanation, February, fraud, free, freedom, freestanding, Global, hts, Indexed, individual, Ineffective, informat, inter, ion, listed, llowed, local, lymphoma, movement, neutropenia, nical, obje, opposed, optimistic, ou, oval, Oversight, Oxley, peer, policy, power, practice, practicing, proced, prove, proxy, real, ree, reliable, remeasured, removal, remove, removed, replicate, residual, resolution, Ri, rig, Serono, simple, sk, speculative, staggered, structure, subscription, Supergen, symbol, Task, ticker, tly, unchanged, uncontrolled, unexpired, whic, widely

Removed: ABSTAINING, acquirer, Alzheimer, annum, applied, August, authorized, Babraham, basic, behalf, body, Bulletin, center, Chiron, collectively, concurrently, constituting, consummation, converted, criteria, dated, David, detailed, diluted, director, discontinued, discover, discovered, Discretionary, dispose, dividing, division, effecting, elevation, exchanged, excluding, Exit, expansion, exploring, feet, final, founded, fully, Glover, granting, hundred, identified, IIa, increasing, incremental, independent, inhibiting, intercompany, intrinsic, Invitrogen, involuntarily, joined, Lane, leader, leased, lender, lesser, liquidation, maximum, mechanism, memorandum, met, mitotic, monthly, Nordisk, note, Novo, obliged, October, office, opportunity, organized, overabundance, owed, parent, participate, percent, Polo, Professor, proposal, prospective, protein, publicly, publish, qualified, raw, recently, recovered, refund, registrant, remit, restriction, retroactively, Rigel, satisfaction, Scheme, Scottish, SEIP, settlement, Similarly, Sir, square, stroke, subscribed, suppressor, thereunto, traded, tumor, type, UK, underlying, undersigned, unexercised, unrecognized, unsecured, variously, vested, voluntary, waived, wholly, withheld, withhold, Xcellerate, Xcellerated

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

CYCC similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

Certification of Chief Executive Officer
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Pursuant to 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Cyclacel Pharmaceuticals, Inc. (the ‘‘Company’’) hereby certifies, to such officer’s knowledge, that:

(i) the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2007 (the ‘‘Report’’) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: May 9, 2007			/s/ Spiro Rombotis
			Spiro Rombotis President and Chief Executive Officer